Phase 1/2 NHT102 inhaled azacitidine DNA hypomethylating agent (DNMT inhibitor) in NSCLC
Trial status
Registered, Not Yet Recruiting
Status as of
Got an update?- Trial ID
- NCT07864584 on ClinicalTrials.gov
- Cancer type
- Non-Small Cell Lung Cancer (NSCLC)
- Stage of research
- First-in-human
- Location
- Canton, OH
- Published in
- New in Oncology - Nov 12, 2026
NHT102-001 is an open-label, multi-center Phase 1/2 trial testing NHT102, an inhaled dry-powder formulation of azacitidine delivered via Nob Hill Therapeutics’ investigational DryNeb device. Azacitidine is a DNA methyltransferase (DNMT) inhibitor (a hypomethylating agent) intended to reprogram tumor biology epigenetically; here, the commercial/scientific bet is that lung-targeted delivery can drive local exposure in the chest while limiting systemic toxicity versus conventional parenteral dosing. Part 1 uses a standard 3+3 dose-escalation (target lung dose range ~7–42 mg per treatment day) to define dose-limiting toxicities and a tolerated dose, then carries forward up to two dose levels with preliminary activity. In Part 2, patients are randomly assigned 1:1 between two selected doses (Simon two-stage–style activity assessment) to choose a recommended Phase 2 dose, and Part 3 expands at that dose for a clearer safety/PK/PD and antitumor signal. The population is advanced, recurrent/persistent stage I–III NSCLC confined to lung/chest region after prior therapy (after prior curative-intent therapy, with no further curative option); management depends on prior therapy and remaining systemic options, so this explores a distinctly regional drug-device approach in patients without another curative option.
More in non-small cell lung cancer
-
New trial · Nov 19, 2026 · NCT07756645
Phase 3 ABBV-1480 PD-1×VEGF bispecific antibody vs pembrolizumab in 1L sqNSCLC -
New trial · Nov 19, 2026 · NCT07393555
Phase 2 sacituzumab govitecan (TROP2 ADC) ± ivonescimab (PD-1×VEGF bispecific) in AGA+ NSCLC -
New trial · Nov 19, 2026 · NCT07899801
Phase 1a/1b zanidatamab (HER2 bispecific antibody) + zongertinib (HER2 TKI) in HER2-mutated NSCLC -
New trial · Nov 12, 2026 · NCT07874490
Phase 2 osimertinib EGFR inhibitor plus cyclosporine A calcineurin/NFAT inhibitor in EGFR-mutant NSCLC -
New trial · Nov 12, 2026 · NCT07871214
Phase 2 pumitamig PD‑L1×VEGF‑A bispecific antibody neoadjuvant platform in resectable NSCLC.
